Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.47 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2083709 | 0.85 | GPR119 (0.51) | GPR119SSTR4ALDH1A1POLBUSP30 | |
| SCHEMBL3335610 | 0.82 | GPR119 (0.54) | GPR119SSTR4ALDH1A1POLBNPC1 | |
| SCHEMBL2087175 | 0.82 | USP30 (0.51) | GPR119ALDH1A1POLBUSP30MAPT | |
| SCHEMBL2083614 | 0.78 | GPR119 (0.44) | GPR119ALDH1A1POLBUSP30 | |
| SCHEMBL8267242 | 0.77 | KDM4E (0.50) | GPR119SSTR4ALDH1A1USP30NPC1 | |
| SCHEMBL23311657 | 0.77 | GPR119 (0.55) | GPR119SSTR4POLB | |
| SCHEMBL8263324 | 0.77 | HTR1A (0.54) | GPR119ALDH1A1POLBNPC1MAPT | |
| SCHEMBL16462805 | 0.77 | ALDH1A1 (0.44) | GPR119ALDH1A1NPC1MAPTMAPK1 | |
| SCHEMBL8266055 | 0.77 | GPR119 (0.57) | GPR119ALDH1A1NPC1MAPTMAPK1 | |
| SCHEMBL14013163 | 0.76 | GPR119 (0.47) | GPR119ALDH1A1POLBUSP30NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | GRM5, GRM1, GRM2 | GPR119 198/4885SSTR4 942/4885ALDH1A1 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.